Fred Middleton
Sanderling Biomedical Ventures

With almost 30 years experience in the biotechnology and biomedical industries, Mr. Middleton currently has active roles as Chairman, CEO, or Director of Sanderling portfolio companies, including Stereotaxis (NASDAQ: STXS), Favrille (NASDAQ: FVRL), CardioNet, Novocell, Cylene, Endocyte and Actimis.

Mr. Middleton was a co-founder of Genentech, where he served as VP of Finance, Administration, Corporate Development, and CFO. He also served as President of Genentech Development Corporation. During his time at Genentech, he concluded more than $200 million in partnering and institutional funding, including Genentech's IPO, a first-ever in the biotechnology industry. Mr. Middleton founded Morgan Stanley Ventures in 1984.

Mr. Middleton earned a B.S. in chemistry from MIT and an MBA with distinction from Harvard Business School.